亚单位疫苗设计与开发中的淋巴分布考量
亚单位疫苗是控制当前和新发传染病的重要平台,淋巴结是产生体液应答的主要部位,抗原递送至淋巴结对有效免疫至关重要。本文综述了通过制剂策略增强亚单位蛋白和佐剂淋巴结暴露的方法,并讨论了可应用于疫苗开发的药代动力学评价。
要点
- 淋巴结是产生体液应答的主要部位,抗原递送至淋巴结对有效免疫至关重要。
- 淋巴结内抗原暴露持续时间与抗体应答相关。
- 皮下接种可直接进入淋巴管,但蛋白亚单位抗原淋巴结摄取效率低,需佐剂并优化制剂策略。
核心结论
- 淋巴结暴露是疫苗设计的关键考量,抗原和佐剂的药代动力学深入分析应成为未来临床前和临床研究的重点。
研究设计与样本
- 综述,概述靶向淋巴系统和延长抗原暴露的制剂策略,并讨论可应用于疫苗开发的药代动力学评价。
主要发现
- 淋巴结是产生体液应答的主要部位,抗原递送至淋巴结对有效免疫至关重要。
- 淋巴结内抗原暴露持续时间与抗体应答相关。
- 当前获批疫苗通常采用肌内注射途径,皮下注射疫苗可直接进入淋巴管,从而可能增强抗原向淋巴结的转运。
- 蛋白亚单位抗原进入淋巴结的效率低,亚单位疫苗需要佐剂刺激初始免疫应答。
- 已开发制剂策略通过增加淋巴摄取或延长注射部位滞留来增强亚单位蛋白和佐剂向淋巴结的暴露。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Subunit vaccines are an important platform for controlling current and emerging infectious diseases. The lymph nodes are the primary site generating the humoral response and delivery of antigens to these sites is critical to effective immunization. Indeed, the duration of antigen exposure within the lymph node is correlated with the antibody response. While current licensed vaccines are typically given through the intramuscular route, injecting vaccines subcutaneously allows for direct access to lymphatic vessels and therefore can enhance the transfer of antigen to the lymph nodes. However, protein subunit antigen uptake into the lymph nodes is inefficient, and subunit vaccines require adjuvants to stimulate the initial immune response. Therefore, formulation strategies have been developed to enhance the exposure of subunit proteins and adjuvants to the lymph nodes by increasing lymphatic uptake or prolonging the retention at the injection site. Given that lymph node exposure is a crucial consideration in vaccine design, in depth analyses of the pharmacokinetics of antigens and adjuvants should be the focus of future preclinical and clinical studies. This review will provide an overview of formulation strategies for targeting the lymphatics and prolonging antigen exposure and will discuss pharmacokinetic evaluations which can be applied toward vaccine development.
引用
- Hartmeier PR, Ostrowski SM, Busch EE, et al. Lymphatic distribution considerations for subunit vaccine design and development. Vaccine. 2024. PMID: 38494411. doi:10.1016/j.vaccine.2024.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。